Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
France Targets Shein, Temu With Fast-Fashion Fees 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
OpenAI Rejects Apple Trade Secret Theft Claims 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Add as a preferred source on Google
TUSTIN, Calif., March 05, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2018 ended January 31, 2018 on March 12, 2018 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Avid's senior management will discuss financial results for the third quarter and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
